Market Exclusive

Analyst Activity – BMO Capital Markets Raises Its Price Target On Intercept Pharmaceuticals (NASDAQ:ICPT) to $221.00

Analyst Ratings For Intercept Pharmaceuticals (NASDAQ:ICPT)

Today, BMO Capital Markets raised its price target on Intercept Pharmaceuticals (NASDAQ:ICPT) to $221.00 per share.

There are 2 sell ratings, 4 hold ratings, 10 buy ratings on the stock.

The current consensus rating on Intercept Pharmaceuticals (NASDAQ:ICPT) is Buy (Score: 2.50) with a consensus target price of $203.50 per share, a potential 73.74% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Intercept Pharmaceuticals (NASDAQ:ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) has insider ownership of 4.50% and institutional ownership of 84.27%.

Recent Trading Activity for Intercept Pharmaceuticals (NASDAQ:ICPT)
Shares of Intercept Pharmaceuticals closed the previous trading session at 111.46 down -5.67 -4.84% with 2,284,591 shares trading hands.

Exit mobile version